These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 9395349)
1. Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. Walker JB; Hussey EK; Treanor JJ; Montalvo A; Hayden FG J Infect Dis; 1997 Dec; 176(6):1417-22. PubMed ID: 9395349 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Hayden FG; Treanor JJ; Betts RF; Lobo M; Esinhart JD; Hussey EK JAMA; 1996 Jan 24-31; 275(4):295-9. PubMed ID: 8544269 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301 [TBL] [Abstract][Full Text] [Related]
4. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet; 1998 Dec; 352(9144):1877-81. PubMed ID: 9863784 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843 [TBL] [Abstract][Full Text] [Related]
6. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. Fritz RS; Hayden FG; Calfee DP; Cass LM; Peng AW; Alvord WG; Strober W; Straus SE J Infect Dis; 1999 Sep; 180(3):586-93. PubMed ID: 10438343 [TBL] [Abstract][Full Text] [Related]
7. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Ryan DM; Ticehurst J; Dempsey MH Antimicrob Agents Chemother; 1995 Nov; 39(11):2583-4. PubMed ID: 8585752 [TBL] [Abstract][Full Text] [Related]
8. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Hedrick JA; Barzilai A; Behre U; Henderson FW; Hammond J; Reilly L; Keene O Pediatr Infect Dis J; 2000 May; 19(5):410-7. PubMed ID: 10819336 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Calfee DP; Peng AW; Hussey EK; Lobo M; Hayden FG Antivir Ther; 1999; 4(3):143-9. PubMed ID: 12731753 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. Mäkelä MJ; Pauksens K; Rostila T; Fleming DM; Man CY; Keene ON; Webster A J Infect; 2000 Jan; 40(1):42-8. PubMed ID: 10762110 [TBL] [Abstract][Full Text] [Related]
12. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. Monto AS; Webster A; Keene O J Antimicrob Chemother; 1999 Nov; 44 Suppl B():23-9. PubMed ID: 10877459 [TBL] [Abstract][Full Text] [Related]
14. Zanamivir: from drug design to the clinic. Elliott M Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1885-93. PubMed ID: 11779388 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Calfee DP; Peng AW; Cass LM; Lobo M; Hayden FG Antimicrob Agents Chemother; 1999 Jul; 43(7):1616-20. PubMed ID: 10390212 [TBL] [Abstract][Full Text] [Related]
16. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Kaiser L; Henry D; Flack NP; Keene O; Hayden FG Clin Infect Dis; 2000 Mar; 30(3):587-9. PubMed ID: 10722450 [TBL] [Abstract][Full Text] [Related]
17. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. Monto AS; Pichichero ME; Blanckenberg SJ; Ruuskanen O; Cooper C; Fleming DM; Kerr C J Infect Dis; 2002 Dec; 186(11):1582-8. PubMed ID: 12447733 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Matsumoto K; Ogawa N; Nerome K; Numazaki Y; Kawakami Y; Shirato K; Arakawa M; Kudoh S; Shimokata K; Nakajima S; Yamakido M; Kashiwagi S; Nagatake T Antivir Ther; 1999; 4(2):61-8. PubMed ID: 10682150 [TBL] [Abstract][Full Text] [Related]
19. Neuraminidase inhibitors in the management of influenza--experience of an outpatient practice. Vogel GE Med Microbiol Immunol; 2002 Dec; 191(3-4):161-3. PubMed ID: 12458352 [TBL] [Abstract][Full Text] [Related]
20. Spotlight on zanamivir in influenza. Cheer SM; Wagstaff AJ Am J Respir Med; 2002; 1(2):147-52. PubMed ID: 14720068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]